SI2419104T1 - Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj - Google Patents

Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj Download PDF

Info

Publication number
SI2419104T1
SI2419104T1 SI201031632T SI201031632T SI2419104T1 SI 2419104 T1 SI2419104 T1 SI 2419104T1 SI 201031632 T SI201031632 T SI 201031632T SI 201031632 T SI201031632 T SI 201031632T SI 2419104 T1 SI2419104 T1 SI 2419104T1
Authority
SI
Slovenia
Prior art keywords
treatment
acetylcholinesterase inhibitor
compound
disease
pharmaceutically acceptable
Prior art date
Application number
SI201031632T
Other languages
English (en)
Inventor
David Beattie
Fei Shen
Jacqueline A. M. Smith
Robert Murray Mckinnell
Ray Chang
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of SI2419104T1 publication Critical patent/SI2419104T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

  1. Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj Patentni zahtevki 1. {(liS,3^,5Z?)-8-[(^)-2-hidroksi-3-(metansulfonil-metil-amino)propil]-8-azabiciklo[3.2.1 ]okt-3-il} amid 1 -izopropil-2-okso-1,2-dihidrokinolin-3-karboksilne kisline ali njegova farmacevtsko sprejemljiva sol za uporabo v kombinaciji z acetilholinesteraznim inhibitorjem za zdravljenje Alzheimerjeve bolezni ali kognitivne motnje.
  2. 2. Spojina za uporabo po zahtevku 1, kjer sta v navedenem zdravljenju navedena spojina in navedeni acetilholinesterazni inhibitor vsak prisotna v odmerku, ki je pod-učinkovit za zdravljenje Alzheimerjeve bolezni ali kognitivne motnje, kadar se ju daje sama.
  3. 3. Spojina za uporabo po zahtevku 1 ali zahtevku 2, kjer je acetilholinesterazni inhibitor donepezilijev hidroklorid.
  4. 4. Spojina po zahtevku 1 za uporabo v kombinaciji z acetilholinesteraznim inhibitorjem za izboljšanje spomina pri bolniku, ki ima spominski deficit.
  5. 5. Spojina za uporabo po zahtevku 4, kjer sta v navedenem zdravljenju navedena spojina in navedeni acetilholinesterazni inhibitor vsak prisotna v odmerku, ki je pod-učinkovit za izboljšanje spomina pri bolniku, ki doživlja spominski deficit, kadar se ju daje sama.
  6. 6. {(15,3/?,5/?)-8-[(i?)-2-hidroksi-3-(metansulfonil-metil-amino)propil]-8-azabiciklo[3.2.1]okt-3-il}amid l-izopropil-2-okso-l,2-dihidrokinolin-3-karboksilne kisline ali njegova farmacevtsko sprejemljiva sol za uporabo v povečanju učinkovitosti acetilholinesteraznega inhibitorja za zdravljenje Alzheimerjeve bolezni ali kognitivne motnje.
  7. 7. Farmacevtski sestavek, ki obsega acetilholinesterazni inhibitor, {(lS,3R,5R)-8-[(i?)-2-hidroksi-3-(metansulfonil-metil-amino)propil]-8-azabiciklo[3.2.1]okt-3-iljamid l-izopropil-2-okso-l,2-dihidrokinolin-3-karboksilne kisline ali njegovo farmacevtsko sprejemljivo sol in farmacevtsko sprejemljiv nosilec.
  8. 8. Farmacevtski sestavek po zahtevku 7, kjer je acetilholinesterazni inhibitor donepezilijev hidroklorid.
  9. 9. Uporaba {(lS,3/?,5/?)-8-[(/?)-2-hidroksi-3-(metansulfonil-metil-amino)propil]-8-azabiciklo[3.2.1]okt-3-il}amida l-izopropil-2-okso-l,2-dihidrokinolin-3-karboksilne kisline ali njegove farmacevtsko sprejemljive soli v izdelavi zdravila za zdravljenje Alzheimerjeve bolezni ali kognitivne motnje pri pacientu, pri čemer navedeno zdravljenje obsega dajanje navedene spojine v kombinaciji z acetilholinesteraznim inhibitorjem.
  10. 10. Uporaba po zahtevku 9, kjer se zdravilo uporabi v odmerku navedene spojine in navedenega acetilholinesteraznega inhbitorja, ki je pod-učinkovit za zdravljenje Alzheimerjeve bolezni ali kognitivne motnje, kadar se ju daje sama.
SI201031632T 2009-04-13 2010-04-12 Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj SI2419104T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders
EP10713790.3A EP2419104B1 (en) 2009-04-13 2010-04-12 Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
SI2419104T1 true SI2419104T1 (sl) 2018-03-30

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031632T SI2419104T1 (sl) 2009-04-13 2010-04-12 Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj

Country Status (23)

Country Link
US (2) US8404711B2 (sl)
EP (1) EP2419104B1 (sl)
JP (1) JP2012523437A (sl)
KR (1) KR20120017421A (sl)
CN (2) CN102395371A (sl)
AU (1) AU2010236734B2 (sl)
BR (1) BRPI1013777A8 (sl)
CA (1) CA2758321A1 (sl)
CY (1) CY1119800T1 (sl)
DK (1) DK2419104T3 (sl)
ES (1) ES2654930T3 (sl)
HR (1) HRP20180018T1 (sl)
HU (1) HUE038141T2 (sl)
IL (1) IL215660A0 (sl)
LT (1) LT2419104T (sl)
MX (1) MX2011010782A (sl)
NO (1) NO2419104T3 (sl)
PL (1) PL2419104T3 (sl)
PT (1) PT2419104T (sl)
RU (1) RU2569056C2 (sl)
SI (1) SI2419104T1 (sl)
WO (1) WO2010120695A2 (sl)
ZA (1) ZA201107490B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2011011972A (es) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
JP6009080B2 (ja) 2012-08-16 2016-10-19 ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 老化及び認知症の予防及び／または治療活性を有する乳酸菌
CN111032038A (zh) 2017-05-24 2020-04-17 H.隆德贝克有限公司 用于治疗阿尔茨海默氏病的药物组合
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
NZ759585A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
EP3661518A1 (en) 2017-07-31 2020-06-10 Theravance Biopharma R&D IP, LLC Methods of treating symptoms of gastroparesis using velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311272E (pt) * 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
DK2419104T3 (en) 2018-02-05
LT2419104T (lt) 2018-02-12
ZA201107490B (en) 2012-06-27
WO2010120695A2 (en) 2010-10-21
CY1119800T1 (el) 2018-06-27
PL2419104T3 (pl) 2018-04-30
US20100261752A1 (en) 2010-10-14
BRPI1013777A8 (pt) 2017-09-19
CN105832735A (zh) 2016-08-10
EP2419104A2 (en) 2012-02-22
RU2011146032A (ru) 2013-05-20
KR20120017421A (ko) 2012-02-28
ES2654930T3 (es) 2018-02-15
IL215660A0 (en) 2012-01-31
JP2012523437A (ja) 2012-10-04
US20140057939A1 (en) 2014-02-27
CN102395371A (zh) 2012-03-28
AU2010236734A1 (en) 2011-11-03
EP2419104B1 (en) 2017-11-08
AU2010236734A8 (en) 2012-02-16
US8404711B2 (en) 2013-03-26
MX2011010782A (es) 2012-01-20
HRP20180018T1 (hr) 2018-02-09
HUE038141T2 (hu) 2018-10-29
WO2010120695A3 (en) 2010-12-02
PT2419104T (pt) 2018-01-31
CA2758321A1 (en) 2010-10-21
NO2419104T3 (sl) 2018-04-07
BRPI1013777A2 (pt) 2016-04-05
RU2569056C2 (ru) 2015-11-20
AU2010236734B2 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
SI2419104T1 (sl) Kombinacije 5-HT4 receptorskih agonistov in acetilholinesteraznih inhibitorjev za zdravljenje kognitivnih motenj
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2404771C3 (ru) Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты
AU2008283989B2 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
HK1142062A1 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
EA200702161A1 (ru) Кристаллическая форма хинолинон-карбоксамидного соединения
JP2012523437A5 (sl)
JP2012508734A5 (sl)
WO2012007159A3 (en) Novel gastro-retentive dosage forms
EA201400183A1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
KR20200020726A (ko) 외상 후 스트레스 장애의 치료를 위한 제제
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
BRPI0515954A (pt) composto e sais farmaceuticamente aceitáveis do mesmo e enanciÈmeros e diaestereÈmeros individuais do mesmo, composição farmacêutica, e, métodos para inibição do transportador de glicina glyt1 em um mamìfero, para a fabricação de um medicamento para inibir o transportador de glicina glyt1 em um mamìfero, para tratar um distúbios neurológicos e psiquiátricos associados com disfunçao de neurotransmissão glicinérgica ou glutamatérgica em um paciente mamìfero e para tratar esquizofrenia em um paciente mamìfero
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
RU2014129508A (ru) Новая комбинация
JP2016514688A5 (sl)
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
TW200640921A (en) Crystalline form of an indazole-carboxamide compound
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial